ADAP - Why Adaptimmune Therapeutics Stock Sank in the First Half of 2021
Shares of Adaptimmune Therapeutics (NASDAQ: ADAP) , a small-cap cancer immunotherapy company, slid by a hefty 21% during the first six months of 2021, according to data from S&P Global Market Intelligence . By contrast, the biotech's shares were among the hottest in the entire healthcare sector last year, with Adaptimmune's stock closing 2020 up by a whopping 349%.
What changed this year compared to 2020? Fortunately, Adaptimmune's clinical pipeline didn't experience any catastrophic setbacks this year. That's the good news. The bad news is that some biotech investors still aren't happy about two interrelated issues.
Image source: Getty Images.
For further details see:
Why Adaptimmune Therapeutics Stock Sank in the First Half of 2021